-5%
M-lucas is indicated for
- Prophylaxis and chronic treatment of asthma
- Acute prevention of Exercise-Induced Bronchoconstriction (EIB)
- Relief of symptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis
Montelukast is a selective leukotriene receptor antagonist (LTRA) that specifically inhibits the cysteinyl leukotriene receptor (CysLT1). Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are inflammatory mediators derived from arachidonic acid metabolism and are released by various immune cells, including mast cells and eosinophils.
These leukotrienes play a significant role in the pathophysiology of asthma and allergic rhinitis by:
✔ Inducing airway inflammation
✔ Causing smooth muscle contraction
✔ Increasing mucus production
✔ Triggering airway edema and bronchoconstriction
By blocking CysLT1 receptors, Montelukast effectively reduces inflammation and bronchial constriction, helping to control symptoms associated with asthma and allergic rhinitis.